Trial Profile
A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs OCS 05 (Primary)
- Indications Glaucoma; Multiple sclerosis; Optic neuritis
- Focus Adverse reactions
- Sponsors Accure Therapeutics; Bionure
- 01 Mar 2021 Results published in the Accure Therapeutics Media Release.
- 15 May 2019 According to a Bionure media release, this study was conducted under the approval of the MHRA, UK.It was backed by a Series A financing led by Alta Life Sciences.
- 09 Apr 2019 Status changed from recruiting to completed.